{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:08:32Z","timestamp":1793758112007,"version":"4.6.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-4093-1","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T09:03:06Z","timestamp":1560157386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China"],"prefix":"10.1186","volume":"19","author":[{"given":"Chunjiang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruobing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9010-4994","authenticated-orcid":false,"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"4093_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.envint.2018.04.011","volume":"116","author":"Y Yang","year":"2018","unstructured":"Yang Y, Song W, Lin H, Wang W, Du L, Xing W. Antibiotics and antibiotic resistance genes in global lakes: a review and meta-analysis. Environ Int. 2018;116:60\u201373. \n                    https:\/\/doi.org\/10.1016\/j.envint.2018.04.011\n                    \n                  .","journal-title":"Environ Int"},{"key":"4093_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.envint.2017.10.016","volume":"110","author":"M Qiao","year":"2018","unstructured":"Qiao M, Ying G-G, Singer AC, Zhu Y-G. Review of antibiotic resistance in China and its environment. Environ Int. 2018;110:160\u201372. \n                    https:\/\/doi.org\/10.1016\/j.envint.2017.10.016\n                    \n                  .","journal-title":"Environ Int"},{"key":"4093_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"HW Boucher","year":"2009","unstructured":"Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1\u201312. \n                    https:\/\/doi.org\/10.1086\/595011\n                    \n                  .","journal-title":"Clin Infect Dis"},{"key":"4093_CR4","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1128\/AAC.04354-14","volume":"59","author":"TH Grossman","year":"2015","unstructured":"Grossman TH, Murphy TM, Slee AM, Lofland D, Sutcliffe JA. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015;59:2567\u201371. \n                    https:\/\/doi.org\/10.1128\/AAC.04354-14\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"key":"4093_CR5","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1128\/AAC.01614-13","volume":"58","author":"JS Solomkin","year":"2014","unstructured":"Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58:1847\u201354. \n                    https:\/\/doi.org\/10.1128\/AAC.01614-13\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"key":"4093_CR6","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1128\/AAC.01288-13","volume":"57","author":"JA Sutcliffe","year":"2013","unstructured":"Sutcliffe JA, O\u2019Brien W, Fyfe C, Grossman TH. Antibacterial activity of Eravacycline (TP-434), a novel Fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57:5548\u201358. \n                    https:\/\/doi.org\/10.1128\/AAC.01288-13\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"key":"4093_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152:224\u201332. \n                    https:\/\/doi.org\/10.1001\/jamasurg.2016.4237\n                    \n                  .","journal-title":"JAMA Surg"},{"key":"4093_CR8","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests f or Bacteria That Grow Aerobically; Approved St andard","author":"CLSI","year":"2012","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests f or Bacteria That Grow Aerobically; Approved St andard. 9th ed. CLSI doc M07-A9. Wayne: Clin Lab Stand Inst; 2012.","edition":"9"},{"key":"4093_CR9","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1128\/AAC.01127-16","volume":"60","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Zhao C, Wang Q, Wang X, Chen H, Li H, et al. High prevalence of Hypervirulent Klebsiella pneumoniae infection in China: geographic distribution, clinical characteristics, and antimicrobial resistance. Antimicrob Agents Chemother. 2016;60:6115\u201320. \n                    https:\/\/doi.org\/10.1128\/AAC.01127-16\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"key":"4093_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ijantimicag.2014.12.022","volume":"45","author":"X Wang","year":"2015","unstructured":"Wang X, Chen H, Zhang Y, Wang Q, Zhao C, Li H, et al. Genetic characterisation of clinical Klebsiella pneumoniae isolates with reduced susceptibility to tigecycline: role of the global regulator RamA and its local repressor RamR. Int J Antimicrob Agents. 2015;45:635\u201340. \n                    https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.022\n                    \n                  .","journal-title":"Int J Antimicrob Agents"},{"key":"4093_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jinf.2015.07.010","volume":"71","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zeng J, Liu W, Zhao F, Hu Z, Zhao C, et al. Emergence of a hypervirulent carbapenem-resistant Klebsiella pneumoniae isolate from clinical infections in China. J Inf Secur. 2015;71:553\u201360. \n                    https:\/\/doi.org\/10.1016\/j.jinf.2015.07.010\n                    \n                  .","journal-title":"J Inf Secur"},{"key":"4093_CR12","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1128\/AAC.02123-13","volume":"58","author":"X Wang","year":"2014","unstructured":"Wang X, Zhang F, Zhao C, Wang Z, Nichols WW, Testa R, et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother. 2014;58:1774\u20138. \n                    https:\/\/doi.org\/10.1128\/AAC.02123-13\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"key":"4093_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1089\/mdr.2013.0100","volume":"20","author":"X Wang","year":"2014","unstructured":"Wang X, Xu X, Li Z, Chen H, Wang Q, Yang P, et al. An outbreak of a nosocomial NDM-1-producing Klebsiella pneumoniae ST147 at a teaching hospital in mainland China. Microb Drug Resist. 2014;20:144\u20139. \n                    https:\/\/doi.org\/10.1089\/mdr.2013.0100\n                    \n                  .","journal-title":"Microb Drug Resist"},{"issue":"suppl_2","key":"4093_CR14","doi-asserted-by":"publisher","first-page":"S196","DOI":"10.1093\/cid\/ciy660","volume":"67","author":"Qi Wang","year":"2018","unstructured":"Wang Q, Wang X, Wang J, Ouyang P, Jin C, Wang R, et al. Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012\u20132016). Clin Infect Dis. 2018;67(suppl_2):S196\u2013205. \n                    https:\/\/doi.org\/10.1093\/cid\/ciy660\n                    \n                  .","journal-title":"Clinical Infectious Diseases"},{"key":"4093_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1749-7922-9-37","volume":"9","author":"M Sartelli","year":"2014","unstructured":"Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW study. World J Emerg Surg. 2014;9:37. \n                    https:\/\/doi.org\/10.1186\/1749-7922-9-37\n                    \n                  .","journal-title":"World J Emerg Surg"},{"issue":"Suppl 3","key":"4093_CR16","doi-asserted-by":"publisher","first-page":"iii25","DOI":"10.1093\/jac\/dkq298","volume":"65","author":"A Pallett","year":"2010","unstructured":"Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant gram-negative bacteria. J Antimicrob Chemother. 2010;65(Suppl 3):iii25\u201333. \n                    https:\/\/doi.org\/10.1093\/jac\/dkq298\n                    \n                  .","journal-title":"J Antimicrob Chemother"},{"key":"4093_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhin.2017.02.014","volume":"96","author":"J Wang","year":"2017","unstructured":"Wang J, Hu J, Harbarth S, Pittet D, Zhou M, Zingg W. Burden of healthcare-associated infections in China: results of the 2015 point prevalence survey in dong Guan City. J Hosp Infect. 2017;96:132\u20138. \n                    https:\/\/doi.org\/10.1016\/j.jhin.2017.02.014\n                    \n                  .","journal-title":"J Hosp Infect"},{"key":"4093_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s12275-016-6146-0","volume":"54","author":"Y Gong","year":"2016","unstructured":"Gong Y, Shen X, Huang G, Zhang C, Luo X, Yin S, et al. Epidemiology and resistance features of Acinetobacter baumannii isolates from the ward environment and patients in the burn ICU of a Chinese hospital. J Microbiol. 2016;54:551\u20138. \n                    https:\/\/doi.org\/10.1007\/s12275-016-6146-0\n                    \n                  .","journal-title":"J Microbiol"},{"key":"4093_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/IDR.S163979","volume":"11","author":"X Yuan","year":"2018","unstructured":"Yuan X, Liu T, Wu D, Wan Q. Epidemiology, susceptibility, and risk factors for acquisition of MDR\/XDR gram-negative bacteria among kidney transplant recipients with urinary tract infections. Infect Drug Resist. 2018;11:707\u201315. \n                    https:\/\/doi.org\/10.2147\/IDR.S163979\n                    \n                  .","journal-title":"Infect Drug Resist"},{"key":"4093_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1128\/AAC.01727-13","volume":"58","author":"M Deng","year":"2014","unstructured":"Deng M, Zhu M-H, Li J-J, Bi S, Sheng Z-K, Hu F-S, et al. Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother. 2014;58:297\u2013303. \n                    https:\/\/doi.org\/10.1128\/AAC.01727-13\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"key":"4093_CR21","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fmicb.2018.00648","volume":"9","author":"X Du","year":"2018","unstructured":"Du X, He F, Shi Q, Zhao F, Xu J, Fu Y, et al. The rapid emergence of Tigecycline resistance in blaKPC-2 harboring Klebsiella pneumoniae, as mediated in vivo by mutation in tetA during Tigecycline treatment. Front Microbiol. 2018;9:648. \n                    https:\/\/doi.org\/10.3389\/fmicb.2018.00648\n                    \n                  .","journal-title":"Front Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4093-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4093-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4093-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T19:07:46Z","timestamp":1591643266000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4093-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4093"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4093-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"12 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study protocols were reviewed and granted by the Ethical Committee of Peking University People\u2019s Hospital (No. 2017PHB163). For the hospitals participated, administrative permissions to access the raw samples were granted by the Research Department of the hospitals participated.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable as no human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"508"}}